Summary
Stryker Corporation's (SYK) second-quarter 2009 filing reveals a mixed financial performance impacted by the ongoing economic downturn. While net sales experienced a slight decline compared to the prior year, driven by weaker demand in the MedSurg Equipment segment and unfavorable currency exchange rates, the Orthopaedic Implants segment showed resilience with constant currency sales growth. The company maintained a strong liquidity position with substantial cash and marketable securities, and generated positive cash flow from operations. However, increased inventory levels and cost of sales percentage suggest pressure on margins and operational efficiency. Investors should note the ongoing legal and regulatory investigations, particularly concerning Stryker Biotech and FDA compliance, which could pose future risks.
Financial Highlights
48 data points| Revenue | $1.63B |
| Cost of Revenue | $536.30M |
| Gross Profit | $1.10B |
| R&D Expenses | $82.60M |
| SG&A Expenses | $617.10M |
| Operating Expenses | $708.20M |
| Operating Income | $389.80M |
| Net Income | $291.30M |
| EPS (Basic) | $0.73 |
| EPS (Diluted) | $0.73 |
| Shares Outstanding (Basic) | 397.40M |
| Shares Outstanding (Diluted) | 399.00M |
Key Highlights
- 1Net sales decreased by 5% to $1.63 billion in Q2 2009 compared to Q2 2008, with unfavorable currency exchange rates impacting reported sales.
- 2The Orthopaedic Implants segment demonstrated strength, with constant currency sales increasing by 5% in Q2 2009 year-over-year, driven by strong performance in hips, knees, trauma, and spine products.
- 3The MedSurg Equipment segment experienced a significant sales decline of 11% (8% on a constant currency basis) in Q2 2009, attributed to weaker demand for certain products amidst the economic slowdown.
- 4Inventories increased by approximately 4% to $991.7 million, with an increase in days sales in inventory to 167 days, attributed to lower production levels and compliance initiatives.
- 5The company reported net earnings of $291.3 million for Q2 2009, a 5% decrease from $305.8 million in the prior year period, with diluted EPS remaining stable at $0.73.
- 6Stryker highlighted ongoing legal and regulatory matters, including investigations into Stryker Biotech for product promotion and misbranding, and FDA warning letters related to manufacturing compliance.
- 7The company maintained a strong balance sheet with $666.3 million in cash and cash equivalents and $1,761.6 million in marketable securities as of June 30, 2009.